- Home
- EVAX vs RDHL Comparison
EVAX vs RDHL Comparison
Compare EVAX & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EVAX | RDHL |
|---|---|---|
| Founded | 2008 | 2009 |
| Country | Denmark | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.7M | 3.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | EVAX | RDHL |
|---|---|---|
| Price | $5.82 | $1.19 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $12.33 | N/A |
| AVG Volume (30 Days) | ★ 98.3K | 74.4K |
| Earning Date | 11-06-2025 | 09-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $7,650,000.00 | ★ $9,550,000.00 |
| Revenue This Year | $128.77 | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 132.17 | ★ 157.62 |
| 52 Week Low | $1.20 | $1.01 |
| 52 Week High | $12.15 | $7.30 |
Technical Indicators
Market Signals| Indicator | EVAX | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 49.31 | 46.62 |
| Support Level | $5.72 | $1.14 |
| Resistance Level | $6.70 | $1.24 |
| Average True Range (ATR) | 0.48 | 0.05 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 38.10 | 31.18 |
Price Performance
Historical ComparisonAbout EVAX Evaxion Biotech
Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion's proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing innovative and targeted treatment options.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.